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 Human parvovirus B19 is a small, spherical, non-enveloped, single- stranded DNA virus. The B19 virion 
contains two capsid proteins, VP1 and VP2. Because is a non-enveloped virus, the B19 resist in the 
products treated by dry-heat or solvent detergent . 
  B19 infects and destroys erythroid progenitor cells of the colony-forming and burst-forming series (CFU-E 
and BFU-E).  
 Globoside, a P blood group antigen, is the major red blood cell receptor used by B19 for attachment and 
entry into the cell. This is why we have included it in our study. Individuals lacking the P blood group Ag are 
not susceptible to B19 infection and have not circulating antibodies  to the virus.  
 Between August and December 2000 using ID- Parvovirus B19 – DiaMed (haemagglutination in gel 
technology), we studied 708 blood donations to detect B19 Ag on the plasma kept in our serum collection, 
we found a prevalence of  0,424 % positive donations. Considering the number of units involved we are 
continuing this study. 
Obtained Results in Blood Donors   
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* Used test: ELISA – RIDASCREEN – R-Biopharm.  
Conclusions: 
             As it is possible to see in our results, one of the patients was recently infected by one blood unit. Our 
objective is not to transfuse this positive blood components to patients in risk, like individuals with 
underlying haemolytic disorders, immunocompromised patients, immunodeficient individuals, 
pregnant women, fetus and newborns.  
Discussion:  
1. Should we consider screening blood donations for B19 Ag ? 
2. Should we deferral this blood donors ? 
3. Should we performe the P blood group antigen in the receptors ? 
Donor P1 Ag PV B19 Ag/n. of blo. donations PV B19 Ab (IgM)* PV B19 Ab (IgG)* 
X Positive (Pos) Pos. since 1996 /       9 Neg Neg 
Y Negative (Neg) Pos. since 1999/        4 Neg Neg 
Z Positive Pos. since 2000/        1 Neg Neg 
